Selvigaltin (GB1211), an orally obtainable small molecule galectin-three inhibitor created for a therapy for liver fibrosis and cirrhosis, was evaluated to assess the influence of hepatic impairment on its pharmacokinetics and safety to address regulatory necessities. the RD group, and examining the indicate on the fold-alter for each variable in https://cesarz221nxi4.wikievia.com/user